CJC-1295 + Ipamorelin vs GHRP-2

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is one preparation holding two separate compounds, a GHRH analogue and a growth hormone secretagogue. Each component has a published literature of its own and a profile of its own on this site. The blend itself has none. No controlled study of the two given together was located. The nearest published work is a 2013 analytical paper describing a method that detects both, among seven peptides, in horse plasma, and a set of recent review articles that list them side by side. Every citation here is attributed to one component or the other.

GHRP-2

GHRP-2, also known by the non-proprietary name pralmorelin, is a synthetic hexapeptide that activates the ghrelin receptor, GHS-R1a. Three of its six residues are D-amino acids, including the non-natural D-2-naphthylalanine, a design feature shared with other synthetic growth hormone-releasing peptides. These compounds were developed by screening for growth hormone release before their receptor had been identified; ghrelin, the receptor's natural ligand, was discovered afterwards. GHRP-2 has been examined in receptor and pituitary cell assays, in animal studies, and in short human endocrine studies that measured hormone secretion. Longer-term human data are sparse, and it is not selective for growth hormone, since rises in other pituitary and adrenal hormones have also been recorded.

How CJC-1295 + Ipamorelin acts

The two components act at different receptors. CJC-1295 is a modified analogue of growth hormone-releasing hormone; a 2006 randomised, placebo-controlled trial in healthy adults reported sustained rises in growth hormone and IGF-1 after a long-acting form of it. Ipamorelin is a pentapeptide that releases growth hormone through the growth hormone secretagogue receptor rather than the GHRH receptor, and its 1998 description in rat pituitary cells, rats and swine reported release without the rise in ACTH and cortisol seen with GHRP-6 and GHRP-2. Nothing published describes what the two do together.

How GHRP-2 acts

GHRP-2 has been reported to act as an agonist at GHS-R1a, a G protein-coupled receptor present on somatotroph cells of the anterior pituitary and on neurons in the hypothalamus. In somatotrophs the receptor couples mainly to Gq and phospholipase C, and the rise in intracellular calcium that follows triggers growth hormone secretion. This route is separate from that of growth hormone-releasing hormone (GHRH), which acts through its own receptor and cyclic AMP. Part of the response is thought to be hypothalamic, through effects on GHRH neurons and on somatostatin signalling. In human studies, modest increases in ACTH, cortisol and prolactin have been reported alongside growth hormone.

The records side by side

• Type: CJC-1295 + Ipamorelin, Two-peptide blend; GHRP-2, Growth hormone secretagogue (GHRP)
• Length: CJC-1295 + Ipamorelin, not recorded; GHRP-2, 6 amino acids
• Molecular weight: CJC-1295 + Ipamorelin, not recorded; GHRP-2, 818.0 g/mol
• Molecular formula: CJC-1295 + Ipamorelin, not recorded; GHRP-2, C45H55N9O6

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.